Renal Cell Carcinoma

With encouraging overall response and disease control rates, lenvatinib plus pembrolizumab has the potential to be a frontline treatment option for non–clear cell renal cell carcinoma.

The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.

The combination of belzutifan and cabozantanib maintained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

A reduced the risk for disease progression by 27% was seen with the combination of cabozantinib added to nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma.

Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.

Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.

A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.

Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.

Adjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part A of the phase 3 CheckMate 914 trial.

Perioperative nivolumab in patients with RCC, at high risk for recurrence, did not see an improved RFS, but analyses within the phase 3 trial could inform future research.

Atezolizumab given post-resection did not improve patients’ with renal cell carcinoma, at increased risk for recurrence, clinical outcomes compared to placebo.

The HCRN-GU16-260 trial reported results for patients with clear cell renal cell carcinoma who received frontline nivolumab followed by salvage nivolumab/ipilimumab on disease progression.

Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.

An expert presents the case of a 68-year-old woman with favorable-risk advanced clear cell RCC for discussion.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.

Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.

Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.

Nazli Dizman, MD, internal medicine resident at Yale Department of Internal Medicine, discusses the role of the gut microbiome in cancers like renal cell carcinoma.

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmD, discussed the most recent data supporting immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for frontline treatment of patients with renal cell carcinoma.

During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.